Document Detail

The potential use of 2-[¹⁸F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma.
MedLine Citation:
PMID:  21553087     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The aim of the study was to evaluate the feasibility of using the hepatocyte-specific positron emission tomography (PET) tracer 2-[(18)F]fluoro-2-deoxy-D-galactose (FDGal) as a tracer for hepatocellular carcinoma (HCC).
METHODS: In addition to standard clinical investigations, 39 patients with known HCC or suspected of having HCC underwent a partial-body FDGal PET/CT (from base of skull to mid-thigh). Diagnosis of HCC was based on internationally approved criteria. FDGal PET/CT images were analysed for areas with high (hot spots) or low (cold spots) tracer accumulation when compared to surrounding tissue.
RESULTS: Seven patients did not have HCC and FDGal PET/CT was negative in each of them. Twenty-three patients had HCC and were included before treatment. FDGal PET/CT correctly identified 22 of these patients, which was comparable to contrast-enhanced CT. Interestingly, FDGal PET/CT was conclusive in 12 patients in whom conventional imaging techniques were inconclusive and required additional diagnostic investigations or close follow-up. Nine patients were included after treatment of HCC and in these patients FDGal PET/CT was able to distinguish between viable tumour tissue as hot spots and areas with low metabolic activity as cold spots. FDGal PET/CT detected extrahepatic disease in nine patients which was a novel finding in eight patients.
CONCLUSION: FDGal PET/CT has great clinical potential as a PET tracer for detection of extra- but also intrahepatic HCC. In the present study, the specificity of FDGal PET/CT was 100%, which is very promising but needs to be confirmed in a larger, prospective study.
Michael Sørensen; Kim Frisch; Dirk Bender; Susanne Keiding
Related Documents :
18647927 - Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate...
25420167 - How i do it: managing radiation dose in ct.
21274717 - Pet/ct without capacity limitations: a danish experience from a european perspective.
16439567 - Evaluation of living liver donors with an all-inclusive 3d multi-detector row ct protocol.
21264977 - In vivo mri of early stage mammary cancers and the normal mouse mammary gland.
21841437 - Use of 1.5 tesla and 3 tesla mri to evaluate femoral head reduction in hip dysplasia.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-05-07
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  38     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-08     Completed Date:  2011-11-28     Revised Date:  2014-09-14    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1723-31     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Biological Transport
Carcinoma, Hepatocellular / metabolism,  radionuclide imaging*
Feasibility Studies
Fucose / analogs & derivatives*,  diagnostic use
Liver Neoplasms / metabolism,  radionuclide imaging*
Middle Aged
Multimodal Imaging / methods*
Positron-Emission Tomography*
Radioactive Tracers
Retrospective Studies
Tomography, X-Ray Computed*
Grant Support
R01 DK074419/DK/NIDDK NIH HHS; R01 DK074419-01/DK/NIDDK NIH HHS; R01 DK074419-05/DK/NIDDK NIH HHS; R01-DK074419/DK/NIDDK NIH HHS
Reg. No./Substance:
0/Radioactive Tracers; 3713-31-3/Fucose; 51146-53-3/2-deoxy-2-fluorogalactose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/...
Next Document:  Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated wi...